vaccin
mainstay
prevent
medicin
mani
infecti
diseas
pregnant
women
unborn
fetus
neonat
repres
three
atrisk
popul
simultan
protect
strateg
vaccin
protocol
pathogenesi
differ
infecti
microb
vari
base
tissu
tropism
time
infect
host
suscept
goal
immun
uniform
across
vaccin
mechanist
understand
infecti
diseas
pathogenesi
immun
respons
therefor
essenti
inform
vaccin
design
implement
appropri
immun
protocol
optim
protect
pregnant
women
fetus
neonat
vaccin
significantli
reduc
health
burden
mani
infecti
diseas
especi
highrisk
popul
pregnant
women
unborn
fetus
neonat
repres
three
popul
highrisk
individu
simultan
protect
vaccineprevent
infecti
diseas
strateg
matern
immun
protocol
infecti
microb
pose
signific
health
risk
pregnanc
divid
three
broad
categori
base
pathogenesi
diseas
outcom
fig
microb
fall
within
one
categori
first
matern
infect
defin
heighten
diseas
sever
pregnant
femal
rare
inconsequenti
transmiss
diseas
fetu
second
fetal
congenit
infect
character
mild
diseas
pregnant
femal
occasion
vertic
transmiss
sever
congenit
diseas
fetu
third
neonat
infant
infect
consid
pose
signific
risk
pregnant
women
unborn
fetus
caus
sever
sometim
fatal
diseas
neonat
infant
lack
protect
matern
immun
follow
birth
vaccin
strategi
employ
differ
micob
within
categori
vari
base
atrisk
individu
ie
mother
fetu
andor
neonateinf
time
greatest
risk
infect
ie
earli
pregnanc
late
pregnanc
postnat
durat
protect
immun
follow
vaccin
review
discuss
evid
suggest
immun
strategi
pregnant
women
tailor
optim
protect
mother
fetu
neonat
infant
individu
review
vaccineprevent
infect
pregnanc
current
vaccin
strategi
employ
reduc
burden
infecti
diseas
includ
influenza
examin
novel
vaccin
platform
consid
applic
may
provid
safe
altern
enhanc
protect
pregnant
women
final
discuss
vaccin
develop
prevent
strategi
combat
emerg
infecti
diseas
includ
zika
pose
threat
pregnant
women
fetus
owe
physiolog
immunolog
chang
support
pregnanc
toler
semiallogen
fetu
pregnant
women
demonstr
increas
suscept
certain
infecti
agent
includ
hepat
e
varicella
zoster
influenza
virus
infect
virus
pregnanc
result
sever
matern
diseas
increas
matern
mortal
associ
pregnanc
complic
observ
frequent
third
trimest
peripartum
period
exampl
case
fatal
rate
among
pregnant
women
infect
hepat
e
viru
estim
compar
gener
popul
approxim
case
varicella
pneumonia
adult
report
pregnant
women
pregnant
women
infect
pandem
influenza
viru
iav
reportedli
time
like
hospit
die
gener
popul
overal
vertic
transmiss
virus
rel
uncommon
advers
pregnanc
outcom
includ
spontan
abort
preterm
birth
still
occur
indirect
consequ
matern
inflamm
report
pandem
australia
new
zealand
indic
among
pregnant
women
hospit
suspect
iav
infect
infant
requir
intens
care
either
stillborn
die
shortli
birth
infant
howev
detect
infect
primari
goal
vaccin
strategi
protect
matern
infect
gener
protect
matern
immun
either
prior
earli
pregnanc
optim
vaccin
prevent
reduc
diseas
induc
steril
immun
ie
immun
complet
prevent
infect
despit
report
reduct
antivir
protein
pregnanc
studi
compar
vaccin
respons
pregnant
nonpregn
women
find
differ
either
magnitud
durat
antibodi
respons
influenza
virus
fact
surveil
data
taiwan
reveal
influenza
vaccin
pregnanc
result
higher
level
seroprotect
vaccin
prior
concept
effect
gestat
age
vaccineinduc
antibodi
respons
center
diseas
control
cdc
advisori
committe
immun
practic
acip
categor
pregnant
women
target
popul
receiv
inactiv
influenza
vaccin
recommend
pregnant
women
immun
trimest
sever
studi
evalu
advers
vaccin
reaction
pregnant
women
conclud
link
pregnanc
complic
advers
fetal
outcom
among
women
vaccin
pregnanc
although
live
attenu
intranas
influenza
vaccin
recommend
pregnant
women
accident
administr
pregnanc
associ
increas
risk
advers
reaction
despit
plethora
data
support
benefit
safeti
influenza
vaccin
pregnanc
coverag
remain
low
less
matern
vaccin
rate
influenza
season
unit
state
misconcept
safeti
benefit
influenza
vaccin
repres
largest
barrier
vaccin
accept
among
pregnant
women
varicella
zoster
viru
vzv
anoth
vaccineprevent
infect
associ
increas
sever
pregnanc
vzv
alpha
herp
viru
caus
agent
varicella
chickenpox
temper
climat
seropreval
among
individu
year
age
estim
almost
infect
occur
prior
year
age
first
modifiedl
vaccin
varicella
zoster
viru
licens
unit
state
recommend
children
month
age
primari
vzv
infect
pregnanc
therefor
uncommon
women
childbear
age
either
infect
immun
women
previous
expos
howev
primari
vzv
infect
week
gestat
associ
risk
congenit
transmiss
diseas
offspr
licens
vzv
vaccin
contain
liveattenu
viru
use
pregnanc
contraind
instead
cdc
recommend
nonpregn
women
childbear
age
vaccin
vzv
least
one
month
prior
concept
herp
viru
infect
vzv
lifelong
reactiv
occur
approxim
individu
result
pain
skin
condit
known
shingl
herp
zoster
reactiv
vzv
howev
associ
increas
diseas
sever
congenit
infect
pregnanc
acut
viral
hepat
caus
hepat
e
viru
hev
emerg
infecti
diseas
caus
sever
diseas
pregnant
women
fatal
rate
endem
region
addit
heighten
matern
diseas
sever
hev
infect
pregnanc
associ
increas
rate
prematur
birth
prenat
mortal
although
vertic
hev
transmiss
rate
high
estim
rel
contribut
fetal
hev
infect
advers
perinat
outcom
unclear
recombin
hev
subunit
vaccin
develop
proven
safe
effect
follow
complet
phase
ii
iii
clinic
trial
commerci
use
current
limit
china
furthermor
vaccin
approv
use
pregnant
women
despit
efficaci
particip
receiv
three
dose
addit
hev
vaccin
candid
test
preclin
pregnant
anim
model
one
recombin
hev
vaccin
shown
safe
highli
immunogen
pregnant
mice
addit
studi
suscept
anim
model
need
confirm
efficaci
follow
viru
challeng
develop
fetus
extrem
vulner
infecti
noninfecti
insult
certain
infecti
agent
often
clinic
silent
healthi
adult
caus
sever
birth
defect
fig
infecti
microb
caus
matern
congenit
postnat
complic
infecti
microb
categor
accord
mechan
transmiss
diseas
popul
greatest
risk
sever
outcom
pregnanc
infect
pathogen
eg
sar
coronaviru
hepat
e
viru
ebola
viru
pregnanc
caus
sever
diseas
pregnant
women
transmit
offspr
infecti
microb
eg
toxoplasma
gondii
rubella
viru
parvoviru
cytomegaloviru
zika
virus
infect
caus
mild
asymptomat
diseas
pregnant
femal
vertic
transmit
fetu
congenit
complic
anoth
categori
microb
eg
bordetella
pertussi
clostridium
tetani
respiratori
syncyti
viru
pose
largest
risk
neonat
birth
mani
infecti
microb
eg
listeria
monocytogen
plasmodium
spp
hiv
vzv
influenza
virus
chlamydia
trachomati
gb
treponema
pallidum
herp
virus
may
caus
overlap
syndrom
depend
time
infect
pregnanc
understand
pathogenesi
infecti
diseas
pregnanc
inform
vaccin
design
implement
appropri
immun
protocol
optim
protect
pregnant
women
fetus
neonat
breach
placent
barrier
critic
development
period
pregnanc
increas
number
pathogen
recogn
caus
congenit
diseas
origin
design
torch
complex
toxoplasma
gondii
rubella
viru
cytomegaloviru
herp
simplex
viru
expand
includ
infecti
agent
includ
zika
viru
develop
congenit
diseas
depend
time
infect
gestat
infecti
burden
pathogenesi
fetu
congenit
syndrom
pathogen
character
varieti
differ
development
abnorm
commonli
impact
hear
vision
central
nervou
system
function
mani
congenit
infect
time
infect
gestat
determin
rel
risk
fetu
dictat
spectrum
diseas
result
exampl
infect
rubella
viru
first
week
gestat
associ
risk
congenit
rubella
syndrom
cr
reduc
risk
week
minim
risk
infect
occur
week
gestat
contrast
risk
congenit
toxoplasmosi
demonstr
highest
third
trimest
pregnanc
hypothes
due
differenti
express
placent
tolllik
receptor
includ
within
first
compar
third
trimest
trophoblast
cell
similarli
matern
infect
listeria
monocytogen
typic
associ
advers
pregnanc
outcom
third
trimest
though
infect
first
trimest
nonhuman
primat
also
lead
rapid
fetal
demis
primari
goal
vaccin
strategi
protect
fetal
infect
gener
protect
matern
immun
prior
pregnanc
congenit
infect
occur
absenc
matern
symptom
vaccin
congenit
agent
ideal
provid
complet
steril
immun
rubella
includ
liveattenu
combin
vaccin
measl
mump
rubella
mmr
confer
lifelong
protect
immun
long
durat
protect
immun
follow
rubella
vaccin
target
popul
includ
children
adolesc
girl
howev
incomplet
vaccin
coverag
lead
paradox
increas
cr
due
increas
averag
age
infect
also
recommend
unvaccin
women
childbear
age
counsel
receiv
rubella
vaccin
least
one
month
prior
concept
implement
largescal
rubella
vaccin
program
result
suffici
populationlevel
immun
signific
reduct
cr
elimin
rubella
viru
sever
develop
countri
includ
unit
state
follow
success
implement
mmr
vaccin
program
cytomegaloviru
cmv
emerg
common
congenit
viral
infect
develop
world
incid
congenit
cmv
vari
base
geograph
region
socioeconom
statu
overal
birth
preval
estim
similar
incid
syndrom
fetal
alcohol
syndrom
contrast
rubella
viru
howev
current
licens
vaccin
avail
cmv
seropreval
approach
develop
countri
vaccin
develop
identifi
prioriti
public
healthcar
goal
cmv
infect
healthi
adult
usual
asymptomat
adapt
immun
respons
insuffici
clear
infect
result
lifelong
latent
infect
myeloid
precursor
cell
although
latent
reactiv
cmv
less
like
caus
congenit
infect
primari
cmv
infect
pregnanc
preconcept
immun
complet
elimin
transplacent
transmiss
congenit
diseas
moreov
pregnant
women
latent
cmv
infect
still
suscept
primari
infect
differ
cmv
strain
shown
distinct
virul
pattern
overcom
challeng
associ
latent
infect
strain
variabl
signific
hurdl
develop
effect
cmv
vaccin
despit
signific
advanc
knowledg
cmv
pathogenesi
precis
immun
target
constitut
fetal
protect
remain
unknown
sever
cmv
vaccin
candid
test
none
provid
complet
protect
infect
fail
protect
reactiv
latent
cmv
research
pathogenesi
cmv
infect
need
defin
immunolog
correl
protect
cmv
transmiss
pregnanc
inform
vaccin
develop
although
associ
congenit
diseas
hepat
b
viru
hbv
anoth
vaccineprevent
infect
cross
placenta
pregnanc
mothertochildtransmiss
remain
common
rout
infect
endem
region
women
activ
viral
replic
chanc
vertic
transmiss
infect
perinat
develop
chronic
hbv
infect
sinc
initi
recommend
routin
hbv
vaccin
children
rate
new
hbv
infect
significantli
declin
unit
state
chronic
hbv
remain
preval
subsaharan
africa
east
asia
although
combin
passiv
activ
immunoprophylaxi
infant
significantli
reduc
perinat
hbv
infect
perinat
transmiss
occur
infect
mother
augment
neonat
prophylact
strategi
cdc
acip
recommend
pregnant
women
identifi
risk
hbv
infect
vaccin
recombin
hbv
vaccin
immun
follow
receipt
hbv
vaccin
longliv
antihbv
antibodi
persist
adult
least
year
longterm
protect
confer
hbv
vaccin
immun
necessari
pregnant
women
alreadi
vaccin
low
risk
infect
owe
limit
exposur
foreign
antigen
blunt
innat
immun
respons
utero
neonat
immun
system
immatur
birth
make
neonat
ie
less
one
month
age
particularli
suscept
infect
infecti
diseas
respons
child
mortal
death
occur
within
one
month
age
neonat
period
immun
system
matur
protect
pathogen
reli
primarili
passiv
immun
maternalderiv
igg
antibodi
human
matern
antibodi
transfer
fetal
circul
placenta
prior
birth
contrast
veterinari
speci
matern
antibodi
transfer
via
colostrum
immedi
follow
birth
regardless
speci
vaccin
pregnanc
increas
circul
matern
antibodi
enhanc
transfer
fetusneon
goal
vaccin
strategi
protect
neonat
infect
gener
robust
matern
antibodi
respons
pregnanc
enhanc
placent
transfer
neonat
protect
exclus
confer
maternalderiv
antibodi
vaccin
aim
protect
infant
priorit
induct
humor
cellular
immun
respons
induct
import
igg
isotyp
associ
highest
placent
transport
effici
femal
moreov
kinet
matern
vaccineinduc
antibodi
respons
effici
placent
antibodi
transfer
halflif
antibodi
neonat
inform
optim
time
vaccin
pregnanc
peak
antibodi
respons
typic
observ
week
follow
immun
vaccin
pregnanc
oppos
concept
like
result
greatest
benefit
neonat
effici
placent
antibodi
transfer
femal
increas
throughout
gestat
less
matern
igg
transfer
fetu
first
week
gestat
significantli
transfer
second
third
trimest
deliveri
fetal
igg
often
exce
matern
level
vaccin
femal
second
third
trimest
pregnanc
like
gener
greatest
level
protect
neonat
precis
time
maximum
protect
debat
controversi
time
pertussi
vaccin
pregnanc
review
elsewher
report
claim
peak
cord
blood
antibodi
concentr
follow
vaccin
second
trimest
other
report
peak
antibodi
concentr
follow
vaccin
third
trimest
antibodi
avid
also
influenc
effici
placent
transfer
higher
avid
antibodi
cross
placenta
greater
effici
low
avid
antibodi
consider
given
develop
high
avid
antibodi
time
vaccin
pregnanc
protect
immun
infant
depend
concentr
avid
maternalderiv
antibodi
halflif
matern
antibodi
infant
also
must
consid
vaccin
develop
administr
maternalderiv
report
halflif
approxim
day
serum
depend
serum
antibodi
titer
present
birth
translat
protect
immun
approxim
first
month
life
infant
pathogen
halflif
antibodi
also
dictat
vaccin
schedul
infant
presenc
maternalderiv
antibodi
interfer
vaccin
efficaci
maternalderiv
antibodi
wane
certain
threshold
infant
mount
activ
vaccin
respons
goal
infant
vaccin
seri
time
vaccin
coincid
time
maternalderiv
antibodi
drop
threshold
neutral
vaccin
antigen
precis
time
event
unpredict
infant
vaccin
schedul
design
vaccin
administ
seri
span
durat
window
minim
suscept
natur
infect
unit
state
infant
vaccin
recommend
month
age
bordetella
pertussi
vaccineprevent
respiratori
pathogen
signific
public
health
import
major
caus
mortal
infant
lack
protect
matern
immun
vaccin
women
pregnanc
howev
significantli
enhanc
transfer
matern
antibodi
fetu
newborn
time
like
protect
antibodi
titer
birth
compar
born
women
vaccin
pregnanc
inactiv
pertussi
antigen
combin
tetanu
diphtheria
toxoid
singl
vaccin
tdap
cdc
acip
recommend
pregnant
women
regardless
previou
vaccin
histori
contrast
vaccin
formul
contain
kill
whole
b
pertussi
organ
tdap
vaccin
contain
select
antigen
confer
rel
weak
transient
protect
immun
declin
year
vaccin
women
either
prior
concept
earli
pregnanc
provid
adequ
neonat
protect
pertussi
consequ
cdc
consid
third
trimest
optim
time
administ
tdap
vaccin
pregnant
women
advers
event
report
follow
tdap
vaccin
gener
mild
report
risk
advers
pregnanc
outcom
relat
tdap
vaccin
pregnanc
despit
consist
evid
support
benefit
safeti
tdap
vaccin
pregnanc
coverag
remain
low
estim
pregnant
women
receiv
tdap
vaccin
unit
state
receipt
tdap
vaccin
pregnanc
also
confer
protect
neonat
tetanu
associ
case
fatal
approach
absenc
medic
care
diseas
caus
toxin
produc
clostridium
tetani
infect
occur
commonli
due
contamin
umbil
stump
follow
deliveri
consequ
incid
diseas
much
greater
develop
countri
matern
vaccin
scarc
perinat
hygien
practic
poor
world
health
assembl
call
elimin
neonat
tetanu
inspir
initi
improv
vaccin
coverag
birth
hygien
countri
high
diseas
preval
part
initi
immun
standard
expand
recommend
pregnant
women
unknown
inadequ
vaccin
histori
receiv
two
dose
toxoidcontain
vaccin
administ
one
month
apart
matern
antitetanu
antibodi
passiv
transfer
fetu
estim
matern
immun
reduc
neonat
tetanu
mortal
respiratori
syncyti
viru
rsv
common
respiratori
viral
pathogen
newborn
infant
account
acut
bronchiol
pneumonia
case
hospit
children
less
year
age
rsv
also
report
caus
sever
diseas
hospit
pregnant
women
infect
occur
third
trimest
therefor
dualli
qualifi
matern
infect
well
licens
vaccin
rsv
current
unavail
sever
vaccin
candid
shown
promis
variou
anim
model
given
import
pathogen
earli
life
vaccin
develop
strategi
focus
matern
immun
three
matern
vaccin
current
clinic
trial
matern
vaccin
rsv
direct
indirect
benefit
neonat
neonat
directli
protect
passiv
transfer
matern
antibodi
placenta
indirectli
protect
vaccin
mother
less
like
transmit
infect
infant
vaccin
pregnant
women
controversi
immun
live
ie
replicationcompet
viral
bacteri
vaccin
gener
contraind
due
theoret
risk
congenit
infect
teratogen
effect
vaccin
strain
howev
report
pregnant
women
unknowingli
immun
live
attenu
rubella
vaccin
case
vaccineassoci
congenit
rubella
infect
live
viru
strain
influenza
yellow
fever
virus
administ
pregnant
women
also
link
pregnanc
complic
vaccin
inactiv
vaccin
influenza
tdap
pregnanc
low
uptak
concern
safeti
among
patient
healthcar
provid
primari
barrier
safeti
vaccin
adjuv
debat
although
neither
tdap
season
influenza
vaccin
recommend
pregnanc
contain
adjuv
retrospect
studi
evalu
safeti
adjuv
pandem
influenza
vaccin
pregnant
women
found
relationship
advers
pregnanc
outcom
conserv
approach
vaccin
protocol
pregnant
women
stem
lack
control
safeti
efficaci
studi
popul
ethic
reason
pregnant
women
exempt
almost
clinic
vaccin
trial
heath
care
provid
less
like
endors
prophylact
treatment
safeti
efficaci
profil
adequ
character
wherea
studi
pregnant
women
possibl
preclin
test
anim
model
may
provid
use
altern
vaccin
preclin
trial
pregnant
anim
model
may
provid
inform
inform
healthcar
polici
pregnant
women
although
differ
length
gestat
placent
structur
fetal
develop
human
anim
model
mani
structur
function
parallel
exist
serv
tractabl
platform
evalu
safeti
efficaci
variou
therapi
pregnanc
similar
human
pregnant
mice
rat
rabbit
hemochori
placenta
rel
short
gestat
larg
litter
advantag
perform
high
throughput
screen
candid
therapeut
safeti
efficaci
preclin
behavior
test
rodent
offspr
proven
promis
avenu
identifi
predict
advers
effect
associ
prenat
drug
exposur
children
rodent
rabbit
model
instrument
test
teratogen
effect
artemisininbas
combin
therapi
treat
malaria
pregnant
women
studi
conclud
drugrel
teratogen
effect
limit
first
trimest
support
world
health
organ
recommend
artemisinin
may
administ
second
third
trimest
pregnant
women
one
limit
mous
rat
model
howev
inabl
recapitul
certain
element
human
congenit
diseas
instanc
murin
cmv
transmit
vertic
human
anim
model
includ
guinea
pig
nonhuman
primat
requir
studi
aspect
diseas
pathogenesi
studi
pregnant
nonhuman
primat
instrument
identif
cell
respons
critic
earli
control
cmv
infect
transmiss
pregnanc
studi
guinea
pig
demonstr
singlecycl
infecti
cmv
vaccin
induc
immun
respons
similar
natur
infect
protect
congenit
infect
guinea
pig
also
use
model
chlamydi
genit
infect
human
experiment
vener
infect
chlamydophila
cavia
mimic
diseas
associ
c
trachomati
human
includ
sexual
perinat
transmiss
guinea
pig
therefor
serv
use
model
test
candid
vaccin
treatment
rabbit
continu
serv
import
model
vener
infect
treponema
pallidum
caus
agent
syphili
associ
congenit
diseas
human
natur
infect
rabbit
associ
speciesspecif
paraluiscanuculi
rabbit
experiment
inocul
human
pallidum
instrument
test
efficaci
candid
vaccin
mani
mammalian
speci
includ
rodent
rumin
nonhuman
primat
suscept
infect
listeria
monocytogen
demonstr
similar
fetal
complic
infect
occur
pregnanc
studi
variou
anim
model
uniqu
contribut
understand
placent
listeriosi
serv
platform
evalu
prevent
strategi
final
mice
cotton
rat
guinea
pig
sheep
suscept
infect
rsv
vaccin
pregnant
anim
facilit
develop
test
matern
immun
strategi
protect
neonat
rsv
base
preliminari
studi
guinea
pig
experiment
rsv
recombin
f
nanoparticl
vaccin
evalu
thirdtrimest
pregnant
women
clintrialsgov
beyond
direct
model
human
congenit
infect
anim
inform
also
gain
studi
relat
veterinari
pathogen
exampl
bovin
viral
diarrhea
viru
bvdv
import
reproduct
pathogen
infect
cattl
worldwid
infect
pregnanc
caus
congenit
infect
diseas
persist
infect
anim
serv
reservoir
within
herd
huge
agricultur
financi
impact
result
signific
resourc
dedic
develop
optim
bvdv
vaccin
vaccin
protocol
consid
variabl
type
time
vaccin
immun
respons
protect
challeng
inform
glean
studi
may
inform
vaccin
develop
optim
protocol
relat
pathogen
pregnant
women
similar
studi
ethic
perform
zika
viru
zikv
uniqu
flaviviru
caus
mild
subclin
diseas
pregnant
women
devast
effect
fetu
neonat
infect
pregnanc
link
spontan
abort
varieti
birth
defect
includ
microcephali
impair
neurocognit
function
sinc
initi
discoveri
african
macaqu
zikv
expand
geograph
rang
evolv
separ
viru
lineag
environment
pressur
result
emerg
virul
substrain
rais
concern
vaccin
escap
mutant
vaccin
approv
combin
uniqu
pathogenesi
divers
mode
transmiss
rapid
global
spread
increas
effort
toward
develop
licens
zikv
vaccin
basic
understand
zikv
biolog
pathogenesi
essenti
develop
effect
vaccin
zikv
although
extrapol
biolog
inform
relat
flavivirus
yellow
fever
west
nile
dengu
virus
zikv
uniqu
characterist
follow
vivo
infect
pose
signific
challeng
vaccin
design
unlik
flavivirus
zikv
tropism
reproduct
tissu
includ
test
semen
sperm
male
placenta
pregnant
femal
hypothes
contribut
sexual
vertic
mode
transmiss
respect
addit
uniqu
tissu
tropism
zikv
persist
reproduct
tissu
follow
clearanc
system
viremia
male
zikv
rna
detect
month
follow
recoveri
symptomat
infect
viru
persist
placenta
pregnant
women
hypothes
contribut
prolong
viremia
popul
evid
viru
persist
suggest
zikv
may
evolv
mechan
evas
host
immun
respons
infect
occur
certain
immuneprivileg
tissu
scenario
involv
persist
zikv
infect
consid
develop
test
candid
vaccin
consid
potenti
viral
persist
semen
vaccin
men
may
serv
addit
strategi
reduc
transmiss
fetu
pregnant
women
may
infect
sex
partner
character
immun
respons
zikv
infect
essenti
determin
correl
protect
vaccin
efficaci
follow
infect
human
nonhuman
anim
zikv
induc
neutral
antibodi
zikv
e
protein
prevent
fetal
infect
demis
administ
pregnant
mice
mhc
class
epitop
identifi
confer
protect
zikv
challeng
immunocompet
mice
date
candid
zikv
vaccin
develop
februari
nine
enter
phase
clinic
trial
vaccin
candid
develop
use
divers
platform
includ
dna
mrna
purifi
inactiv
liveattenu
viru
mani
test
nonpregn
mous
nonhuman
primat
model
abil
gener
immun
respons
mimic
respons
natur
infect
protect
zikv
challeng
candid
dna
plasmid
vaccin
induc
robust
cellular
immun
neutral
antibodi
respons
nonhuman
primat
immunocompet
mice
confer
complet
protect
lethal
zikv
challeng
type
interferon
receptor
defici
ifnar
mice
lnpmrna
vaccin
induc
similar
protect
immun
character
high
neutral
antibodi
titer
steril
immun
zikv
challeng
nonpregn
mice
nonhuman
primat
whether
candid
vaccin
induc
protect
immun
pregnant
femal
suffici
prevent
fetal
neonat
infect
requir
evalu
also
whether
preexist
immun
flavivirus
cocircul
zikv
includ
dengu
viru
west
nile
viru
affect
efficaci
zikv
vaccin
pregnant
femal
consid
preclin
anim
model
human
clinic
trial
convent
vaccin
formul
either
live
attenu
pathogen
strain
inactiv
pathogen
notabl
disadvantag
platform
live
attenu
vaccin
replicationcompet
potenti
becom
virul
caus
advers
effect
individu
weaken
immun
system
due
unknown
risk
develop
fetu
live
viru
vaccin
recommend
use
pregnant
women
inactiv
vaccin
hand
associ
risk
reacquisit
virul
tend
induc
weaker
host
immun
respons
effort
balanc
safeti
immunogen
led
develop
sever
novel
vaccin
technolog
includ
replicationdefici
nanoparticlebas
vaccin
selfassembl
recombin
viruslik
particl
vlp
replicationcompet
recombin
viral
vector
singlecycl
infecti
virus
infect
replic
host
cell
nanoparticl
deliveri
platform
includ
liposom
synthet
polym
engin
enhanc
select
tissu
home
high
potenc
target
deliveri
antigen
nativ
conform
recombin
vlp
combin
highli
immunogen
surfac
viral
protein
encapsul
adjuv
devoid
infecti
nucleic
acid
induc
strong
cellular
humor
immun
respons
nanoparticl
vlp
vaccin
devoid
genet
materi
therefor
replic
incompet
enhanc
safeti
vulner
individu
although
current
product
yield
cost
associ
technolog
may
prohibit
largescal
use
platform
may
wellsuit
target
use
highrisk
popul
includ
pregnant
women
sinc
first
nanoparticlebas
vaccin
licens
hepat
b
viru
technolog
appli
develop
licens
vaccin
human
papilloma
viru
hepat
e
viru
malaria
demonstr
safeti
efficaci
pregnanc
yet
document
recombin
virus
engin
combin
antigen
gene
one
viru
structur
gene
anoth
target
manipul
viru
genom
use
remov
virul
gene
enhanc
safeti
alter
envelop
protein
chang
cell
tropism
recombin
virus
engin
retain
abil
infect
replic
host
preserv
infecti
potenti
enhanc
gener
innat
adapt
immun
respons
mimic
natur
infect
recombin
viru
vaccin
howev
warrant
care
consider
safeti
vector
especi
pregnant
women
safeti
efficaci
profil
viral
vector
platform
establish
engin
new
antigen
target
viral
genom
rel
simpl
requir
extens
revalid
safeti
efficaci
influenc
vector
viru
significantli
reduc
time
develop
manufactur
vaccin
new
viral
pathogen
virus
mani
differ
famili
use
vector
provid
infect
host
elicit
product
immun
respons
without
caus
diseas
note
poxvirus
practic
vector
due
eas
growth
manipul
vitro
wide
host
rang
robust
induct
protect
immun
respons
although
vaccinia
viru
vector
contraind
pregnanc
due
risk
dissemin
diseas
recent
test
raccoonpoxvirusvector
rabi
vaccin
pregnant
mice
prove
safe
effect
novel
vaccin
platform
base
genet
engin
creation
target
lossoffunct
mutat
viral
genom
revers
genet
technolog
contribut
identif
sequenc
within
viral
genom
essenti
infect
replic
vivo
possibl
engin
recombin
viru
vaccin
target
mutat
costand
timeeffici
manner
contrast
inactiv
vaccin
revers
genet
allow
control
manipul
viral
genom
target
specif
process
viru
life
cycl
enabl
product
vaccin
strain
maximum
efficaci
safeti
repres
anoth
promis
altern
convent
attenu
kill
viru
vaccin
among
safest
recombin
vaccin
approach
singlecycl
infecti
sci
virus
develop
influenza
viru
iav
backbon
delet
truncat
viral
protein
necessari
complet
viru
life
cycl
within
host
genet
modif
render
viru
replicationincompet
capabl
infect
induc
immun
respons
host
infecti
capac
sciiav
vaccin
result
strong
cellular
humor
immun
respons
without
risk
advers
effect
associ
liveattenu
vaccin
strain
studi
nonpregn
mice
demonstr
singl
dose
sciiav
vaccin
confer
protect
heterosubtyp
lethal
challeng
without
advers
effect
similar
safeti
efficaci
profil
sciiav
replic
ferret
pig
model
studi
pregnant
anim
perform
compar
risk
associ
live
viru
vaccin
concern
efficaci
inactiv
vaccin
novel
vaccin
platform
nanoparticlebas
technolog
vlp
replicationdefici
virus
proven
benefit
addit
safeti
efficaci
studi
pregnanc
model
warrant
valid
expand
use
vaccin
platform
pregnant
women
tabl
conclus
strateg
immun
women
either
prior
pregnanc
elimin
substanti
reduc
risk
matern
fetal
neonat
infect
diseas
effect
immun
protocol
depend
efficaci
vaccin
induc
protect
immun
respons
time
vaccin
deliveri
pregnanc
synchron
peak
vaccin
respons
period
greatest
suscept
host
optim
vaccin
protocol
achiev
goal
requir
understand
mechan
infect
pathogenesi
diseas
pregnanc
success
implement
vaccin
protocol
pregnant
women
requir
consider
addit
challeng
frequenc
unplan
pregnanc
access
prenat
health
care
human
surveil
data
provid
correl
clue
charact
specif
infect
mechanist
understand
requir
addit
studi
compar
anim
model
system
